Active Biotech AB (publ) (STO:ACTI)
Sweden · Delayed Price · Currency is SEK 5.22
+0.12 (2.35%)
Jul 24, 2026, 5:18 PM CET
Active Biotech AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
134.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRLAB Therapeutics AB | 92.46M |
| Nanologica AB | 31.83M |
| Alzinova AB | 25.66M |
| Biovica International AB | 13.49M |
| Elicera Therapeutics AB | 10.64M |
| NextCell Pharma AB | 9.24M |
| Xintela AB | 2.59M |
| Simris Group AB (PUBL) | 1.88M |
Active Biotech AB News
- 2 months ago - Active Biotech AB Quarterly report: Q1 2026 - Filings
- 3 months ago - Active Biotech AB Slides: Company presentation - Filings
- 4 months ago - Active Biotech AB Slides: Company presentation - Filings
- 5 months ago - Active Biotech AB Annual report: Q4 2025 - Filings
- 5 months ago - Active Biotech AB Quarterly report: Q4 2025 - Filings
- 8 months ago - Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US - Finanz Nachrichten
- 9 months ago - Active Biotech AB Slides: Company Presentation - Filings
- 9 months ago - Active Biotech AB Quarterly report: Q3 2025 - Filings